AI
OBIO icon

Arena Investors’s Orchestra BioMed OBIO Stock Holding History

Arena Investors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43,526
Closed -$434K – 174
2022
Q2 		$434K Hold
43,526
– – 0.19% 77
2022
Q1 		$431K Buy
+43,526
New +$430K 0.28% 61

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Arena Investors's OBIO Position: Q3 2022 in Review

Arena Investors sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 43,526 shares — an estimated $434K sold.

Arena Investors first reported a position in OBIO in Q1 2022 and held it in 2 quarters. The position peaked at $434K in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Arena Investors reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Arena Investors sold 43,526 Orchestra BioMed shares in Q3 2022, an estimated $434K.
  • Arena Investors first reported a position in Orchestra BioMed in Q1 2022 and held it in 2 quarters.
  • Arena Investors's Orchestra BioMed position peaked at $434K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Arena Investors's 13F filing for Q3 2022, filed 2 Nov 2022.